Hematopoietic Progenitor Cell (HPC) mobilization should take into consideration efficacy, predictability, convenience and cost. Despite many different schemas available, the optimal growth factor regimen for chemo-mobilization is still debatable. The standard growth factor used in HPC mobilization is filgrastim (G-CSF) 10mcg/kg/day, administered subcutaneously. Patients usually receive daily G-CSF injections after chemotherapy in average of 10 days before starting apheresis. Medicare patients have to go to hospital or clinic every day to have their G-CSF injections given. We retrospectively evaluated our experience with pegylatedfilgrastim given in conjunction with a subsequent short course G-CSF in 15 patients (8F/7M) with multiple myeloma (n¼6) and lymphoma (n¼9) who underwent chemo-growth factor HPC mobilization for high-dose chemotherapy and autologous stem cell transplantation. Median age was 68 (52-78). Chemotherapy regimen used for mobilization was at the discretion of the transplant physician and included cyclophosphamide (n¼2), DV-PACE (n¼5), DHAP (n¼2), ESHAP (n¼2), EPOCH (n¼2), ICE (n¼1), mostly combined with Rituximab. We planned ahead of time that chemotherapy is completed by the end of the week so that the patient could spend the weekend at home and receive pegfilgrastim at a single fixed dose (6 mg) subcutaneously in the following week with a median 3 (2-4) days after the last day of chemotherapy. At the time of recovery when median WBC was 0.6/mcL (0.1-3.8), daily G-CSF, at a median dose of 6 mcg/ kg/day (5-12) was initiated in 5 (4-7) days after the dose of pegfilgrastim. Five patients (33%) received additional Plerixafor. HPC collection was started based on peripheral CD34 count in a median 3 days (1-6) after the initiation of G-CSF and in 16 days (11-18) after the initial chemotherapy administration. After 2 days (1-3) of apheresis, all patients but one had adequate (>2 x 10 6 ) CD34+ cells/kg in HPC product. Median CD34+ cell count on peripheral blood on day+1 apheresis was 32 (4.6-407) x 10 6 /kg. All patients had full myeloid recovery and median time to ANC>500 x 3 consecutive days was 11 days (10-18) days. No graft failure was observed. All patients tolerated the mobilization regimen well with no serious side effects. Our preliminary data suggest that single dose pegfilgrastim in conjunction with low dose short course G-CSF can provide satisfactory HPC mobilization and be considered an alternative convenient growth factor regimen for select patients. A prospective study is currently underway in our institution. (Table) . In the 68 CBU thawed at MSKCC, the average decrease in CD34+ cell viability post-thaw compared to that of the segment was 1.9% (SD:+/-3.9%; p < 0.001) & ranged -11.0% to +12.0% with the lowest post-thaw CD34+ cell viability being 82% (Figure 1) . Moreover, despite potential differences in laboratories and flow cytometric gating, the number of viable CD34+ cells in the unit post-thaw correlated with both the pre-cryopreservation viable CD34+ counts and the results of the segment (Table) . The median viable CD34+ cell recovery (ratio of post-thaw to segment viable CD34+ counts) was 128% (SD:+/-43.2). In contrast, however, postthaw CFU had weak correlation with pre-cryopreservation and segment values (Table) .
Conclusions: Testing of CBU segments can accurately measure the potency of the frozen CB products, & segment calculations may even underestimate the post-thaw CBU CD34+ cell content. Although the decrease in post-thaw CBU CD34+ cell viability was statistically significant, this difference was too low to be clinically relevant. The poor correlation between segment and post-thaw CFU likely reflects significant inter-laboratory assay variability.
These findings indicate that the processing procedures, cryopreservation technology and thaw/dilution methodology generate high quality units and that testing segment CD34+ cell counts and the percentage of viable cells can predict the post-thaw potency. Whether these findings can be generalized to other CB banks and transplant centers requires further investigation. Results: Of the recipients 101 were MICA-129 MM (14%), 363 MV (52%), and 239 VV (34%). Of the donors 106 were MICA-129 MM (15%), 375 MV (53%), and 229 VV (32%). 27% of the pairs were MICA mismatched, 9 pairs had double (one 10/10 and eight 9/10) and 182 had single mismatches (83 10/10 and 99 9/10). At 0.01 significance level, there was no association between any outcome and MICA mismatch or MICA-129 Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S156
